Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00564954 · ClinicalTrials.gov registry record · Phase 4
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT00564954 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT00564954, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
Interventions
- DRUG Placebo
- DRUG Dex-methylphenidate hydrochloride extended-release (Focalin XR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2007-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00564954
The ClinicalTrials.gov registry entry for NCT00564954 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00564954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00564954 about?
NCT00564954 is a clinical study titled "A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)". This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
What is the current status of trial NCT00564954?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2007-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00564954?
The interventions under investigation include: Placebo (DRUG), Dex-methylphenidate hydrochloride extended-release (Focalin XR) (DRUG).
Who is sponsoring clinical trial NCT00564954?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.